A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO

Project: Research

Project Details

StatusActive
Effective start/end date19/05/23 → 18/05/25

Keywords

  • Clinical Trials
  • Vitiligo
  • Dermatology